Canopy Growth Corporation (WEED) Earnings Call Transcripts

Canopy Growth Corporation's Latest Earnings Call - Q4 FY2026

Canopy Growth Corporation reported its fourth quarter fiscal 2026 results, highlighting a net revenue of $71.2 million, a 10% increase year-over-year, driven primarily by growth in the Canadian medical and international cannabis segments. The company achieved a full-year revenue of $285 million, reflecting a 6% increase, with management indicating that they expect continued growth momentum into fiscal 2027. Notably, the acquisition of MTL Cannabis is expected to yield significant cost synergies and enhance Canopy's market position in Canada and Europe, although management cautioned about potential near-term revenue pressures as integration efforts continue.

Reported metrics

Guidance from management

Management expects to achieve positive adjusted EBITDA during fiscal 2027, driven by continued revenue growth and cost reductions. They also indicated a focus on expanding into the U.K. and enhancing product offerings in Canada and Europe.

What management said

Yes. I would say on the sales and marketing piece of the SG&A, Kenric, a lot of the spend, it's tied more to Canada than in Germany. I think where we see the biggest unlock in Germany would be in getting some of the MTL flower. And Luc, I don't know if you want to...

Yes, absolutely. We still see tremendous growth potential in Europe. Our challenge in fiscal 2026 were driven by supply chain issues where we weren't able to consistently supply flower. And we're in a much better place now as demonstrated in the last 2 quarters where we've seen sequential growth. And you have to remember that the market -- the European market as a whole still have a lot of potential for growth penetr...

What analysts pressed on

Analysts expressed concerns regarding the impact of changes in reimbursement practices on the Canadian medical cannabis segment, particularly for veteran users. There were also questions about the competitive landscape in international markets, especially Germany, and how Canopy plans to navigate these challenges while maintaining market share.

Main topics on the call

• Acquisition of MTL Cannabis — The acquisition of MTL Cannabis has positioned Canopy as the leading Canadian medical cannabis business by revenue, with management stating, "We are already executing on $6 million of our targeted $10 million of annualiz...
• Revenue Growth in Canadian Segments — Canopy reported a 20% increase in net revenue from the Canadian adult-use market and an 18% increase from the medical segment, with CEO Luc Mongeau noting, "The growth was driven by product innovation focused on the fast...
• International Business Performance — The international cannabis segment saw a remarkable 68% year-over-year revenue growth in Q4, driven by improvements in Poland and Germany. Management emphasized, "We believe strengthened capabilities will become increasi...
• Cost Management and Financial Position — Canopy has streamlined its operations, resulting in a 15% reduction in general and administrative expenses. CFO Tom Stewart stated, "We ended the year with $365 million of cash... our net cash position was $131 million,"...

Read the full Canopy Growth Corporation transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 33 Canopy Growth Corporation earnings call transcripts on record, spanning February 14, 2020 to August 7, 2026. Based on this history, Canopy Growth Corporation reports quarterly. The most recent call on file is dated August 7, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

WEED

Exchange

TSX

Country

CA

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

33

First call

February 14, 2020

Most recent

August 7, 2026

Reporting cadence

quarterly